Module B: Market Opportunities in Biosimilars
12:00 – 12:35
Analysing market intelligence to identify opportunities and areas of growth
• Understanding what makes Biosimilars uptake more difficult than generics
• What is the size of the pie? Analysing current growth statistics and realizing the gap in performance versus potential
• Identifying the key therapeutic areas for Biosimilars that hold the greatest opportunity
• Where are the future opportunities for greatest growth - US, EU or India? Where should you invest?
Peter Wittner, Senior Consultant, Interpharm Consultancy
12:35 – 13:00
How to successfully navigate a complicated regulatory environment
• Identifying the regulatory mechanisms from both production and supply angles in the US and India
• Compiling the right quantity and quality of data to meet international requirements of comparability and interchangeability
• How to mitigate effects of changing legislation: Avoiding common pitfalls
• Minimizing cost burden of compliance with regulatory standards
Cecil Nick, VP Biotechnology, Parexel
Richard Morton, Director Reimbursement & Market Access, Parexel
13:00 – 13:25
Reviewing cost-effective solutions to support your Biosimilars strategy
• Are low outsourcing costs in emerging markets for research and production worth the gamble?
• Understanding different challenges of outsourcing bio pharma as opposed to generics
• Transfer of sensitive material: How to ensure reliability in the supply chain
• Weighing up the added financial investment of a good marketing force to build brand awareness and achieve success
• Biopartnering: Opportunities for partnering with Big Pharma and generic companies for licensing deals and strategic alliances
Rahul Padhye, Head of Corporate Development, Reliance Life Sciences
13:25 - 13.45
Panel Discussion
Return to Agenda
|
